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The increased risk of cancer in immunosuppressed 
renal transplant recipients and the types of tumors 
most commonly found in these patients have been 
clearly documented since the first reports appeared 
more than 20 years ago (1-4). In contrast, the risk 
of cancer in patients treated by dialysis is less well 
established and has been a subject of some debate. 
This review will summarize the studies that have 
been conducted to discern the risk of cancer in 
dialysis patients; the issue of monitoring this patient 
population for cancer will then be addressed. 
A Review of the Research 
Reports have variously contended that end-stage 
renal disease (ESRD) patients maintained on dialysis 
have a risk of cancer similar to, greater than, or less 
than that of the general population. Despite this lack 
of consensus, there has been general agreement that 
the types of cancers diagnosed in chronically dialyzed 
patients are usually those found more commonly in 
the general population (5-1 l), rather than the rela- 
tively rarer tumors, such as lymphomas, reticulum 
cell sarcomas, liver primaries, and nonmelanoma 
skin cancers expressed in higher rates among trans- 
plant recipients (1-4). Table 1 provides an overview 
of these studies conducted on the risk of cancer 
among dialysis patients. 
That patients on dialysis might experience an in- 
creased risk of cancer relative to the general popu- 
lation was suggested by Matas and colleagues ( 5 )  in 
a study of 78 chronic dialysis patients. Using age- 
specific incidence rates from another region of the 
United States as a comparison, the authors con- 
cluded that the observed incidence of cancer in their 
patient population was seven times higher than ex- 
pected ( p  < 0.02). The following year, an Australian 
study reported that 6 of 47 patients accepted for 
home dialysis training were diagnosed with cancer 
after an average of 12 months on dialysis (6). These 
reports were among the first to observe that dialysis 
patients might experience an increased risk of cancer 
Address correspondence to: Friedrich K. Port, MD, MS, 315 
West Huron, Suite 340, Ann Arbor, MI 48103. 
Seminars in Dialysis-Vol 4. No 4 (Oct-Dec) 1991 pp 253- 
257 
relative to the general population, although the pa- 
tient groups studied were small. 
A 1977 report also suggested that maintenance 
dialysis might contribute in some way to an increased 
cancer risk (7). This larger study examined 712 pa- 
tients started on hemodialysis between 1967 and 
1976 at two New York dialysis units. A significant 
excess of both reticulum cell sarcoma (16.8 times 
higher than the expected incidence) and kidney can- 
cer (risk ratio of 11.7) were found, but only among 
women. These initial studies were followed by addi- 
tional reports, the interpretation of which suffered 
from the studies’ examination of highly selected 
dialysis populations or by using a comparison with 
cancer mortality, rather than cancer incidence, data 
(8). One chart review of 499 dialysis patients, for 
example, found that this group’s risk of malignant 
neoplasms was more than 3.8 times higher than 
expected for all types of cancer combined (9). 
A larger British study included 165 1 patients from 
six large dialysis centers (10). Using the time from 
first dialysis through 1976 as the study period, the 
only type of cancer noted to have a significant excess 
of incidence (and of mortality) was non-Hodgkin’s 
lymphoma (NHL). Subsequently, a larger European 
Dialysis and Transplant Association Registry survey 
comprising data from 1086 centers in 30 countries 
found that the tumors most frequently diagnosed 
after the start of regular dialysis therapy reflected 
those most common in the general population (1 1). 
As in other groups of dialysis patients, this European 
survey found a greater than expected proportion of 
renal and urogenital cancers (in both sexes) than of 
all other sites of malignancy (1 1). The frequent di- 
agnosis of genitourinary cancers was confirmed by a 
report on 7257 dialysis patients from the Australia 
and New Zealand Combined Dialysis and Trans- 
plant Registry, which also found a higher than ex- 
pected incidence of lung neoplasms ( 12). 
A nationwide Japanese survey revealed that the 
most frequent malignant tumor diagnosed in the 
dialysis population was gastric cancer (1 3). This find- 
ing is not unexpected as gastric cancer is most fre- 
quent among the general population in Japan. Again, 
a high incidence of gynecologic and urinary cancers 
was also noted. A more recent Japanese study re- 
ported a high incidence of renal cell carcinoma di- 
agnosed in a prospectively followed dialysis cohort 
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TABLE 1. Studies on cancer risk in dialysis patients 
Number of First Author, Year Dialysis 
Patients (Ref.) 
Results (n) Comments 
Descriptive Studies without Assessment of Risk 
Miach, 1976 (6) 
Jacobs, 1981 39,434 Proportionately most common tumors (500) 
47 Tumors include: kidney (2 ) ,  skin (2), stom- 
ach ( I ) ,  intestinal carcinoid (1). 
after dialysis include: prostate, bronchus, 
and colon among males, and breast, cer- 
vix, and bladder among females. 
the lung, were most frequent. 
multiple myeloma (I), lung ( I ) ,  liver ( I ) ,  
kidney (I), rectum (I), unknown site (I). 
(11) 
Sheil. 1985 (12) 7,257 Genitourinary tumors, followed by those of 
OShea, 1990 324 Tumors include: bladder (4), breast (3), 
(15) 
Cohort Studies with Some Assessment of Risk 
Matas, 1975 ( 5 )  646 
Slifkin, 1977 (7) 7 12 
Sutherland, 88 
1977 (8) 
Herr, 1979 (9) 499 
Kinlen, 1980 1,651 
(10) 
Ota, 1981 (13) 2 1,340 
Bush, I984 (16) 834 
Digenis, 1986 328 
Ishikawa, 1990 96 
(17) 
(14) 
Excess of all cancers combined. Tumors in- 
clude: breast (3), kidney (2), leukemia ( I ) ,  
lung ( I ) ,  insulinoma (l), thyroid (1). cer- 
vix in situ (1). 
cell sarcoma (2) only among women. One 
of two kidney cases was diagnosed at au- 
topsy. 
Excess of all cancers combined. Tumors in- 
clude: kidney (I), nose (I), and splenic 
flexure ( I ) .  
Excess of all cancers combined. Tumors in- 
clude: colon (3), multiple myeloma (2), 
stomach (2), rectum (2), histiocytic lym- 
phoma (2 ) ,  pancreas ( l ) ,  larynx (l), ovary 
(l), unknown site (I). 
Excess of all cancers combined. Tumors in- 
clude: non-Hodgkin’s lymphoma (4), kid- 
ney (3), thyroid (2), breast (l), stomach 
(1). bladder ( l ) ,  brain (I), cervix in situ 
(,I), unknown site (1). 
more common among patients on dialysis 
than in general population. Excess mortal- 
ity due to all cancers combined. 
expected (15.6). 
Excess of kidney cancer (2) and reticulum 
Unnary tract, uterine, and liver tumors 
Number of observed cancers (7) lower than 
No evidence for an excess of cancer. 
Carcinomas diagnosed after an average 
A cancer prevalence survey of patients 
12 months on dialysis. 
treated by dialysis and/or transplanta- 
tion. 
A history of cancer in 2% prior to di- 
alysis. 
Recommend a diagnostic protocol for 
bladder tumors for symptomatic pa- 
tients. 
Compared the cancer rates for their co- 
hort t6 those of another geographic re- 
gion. 
and all ages to Third National Cancer 
Survey data. 
Compared rates for all sites of cancer 
Compared a combination of cancer inci- 
dence and mortality rates to mortality 
rates. 
One cancer patient had previous immu- 
nosuppressive therapy. 
Compared mortality rates to national 
data. Compared incidence data to data 
from a local registry. 
Based on survey data with a 53% re- 
sponse rate. 
Incomplete identification of hospital co- 
Compared incidence data to mortality 
Twelve patients had a prior transplant. 
hort studied. 
data. 
Renal cell carcinoma incidence of one case 
per 249 patient-years. 
(14). A hospital-based study of 324 dialysis patients 
in Spain has also confirmed the frequent diagnosis 
of genitourinary tumors (four urinary bladder can- 
cers) (15). The authors recommended that a diag- 
nostic protocol for urinary bladder tumors be fol- 
lowed in all symptomatic patients. 
One of the few studies to conclude that the inci- 
dence of cancer is lower among uremic patients than 
among the general population of the same geo- 
graphic area was published in 1984 (16). The study 
group consisted of 834 uremic patients referred to a 
London hospital between 1966 and 1983 for dialysis 
or transplantation. These findings, however, should 
be considered with caution, as the researchers them- 
selves recommended, because they could not be cer- 
tain of complete ascertainment of their patient co- 
hort. Another hospital-based study, conducted in 
Canada, reviewed records of 328 patients treated by 
continuous ambulatory peritoneal dialysis from 
1977 to 1985. Although nine patients developed 
cancer, no excess risk was detected in this relatively 
small group of dialysis patients ( 17). 
In terms of study design, three of the more recent 
investigations into the risk of cancer in dialysis pa- 
tients can be viewed as the most comprehensive 
(Table 2), based on the following criteria. 1) They 
examine data on cancer incidence, rather than can- 
cer mortality. This is a strength, given the inherent 
problems of cause of death information (1 8, 19). 2) 
They exclude from study any patients who were 
diagnosed with cancer prior to treatment by dialysis 
or those whose renal failure was attributed to malig- 
nancy. 3) They make use of the general population’s 
cancer experience, by referring to the appropriate 
population-based cancer incidence data for statistical 
comparison. These studies use general population 
cancer-incidence data derived from the National 
Cancer Institute’s Surveillance, Epidemiology, and 
End Results (SEER) program, which includes a se- 
lected sample of approximately 10% of the U.S. 
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Number of 
Dialysis Patients First Author, Year (Ref.) 
Cancer Cases 
Site n 
Results ( p  value) 




Kantor, 1987 (19) 28,049 Non-Hodgkin's 7 RRC,d 2.6 (< 0.05) 
Port, 1989 (20) 4,161 Kidney 6 SIR 5.0 (< 0.005) 
Uterus 6 SIR 4.3 (< 0.005) 
Prostate 13 SIR 1.7 (< 0.05) 
lymhoma 
SIR, standardized incidence ratio. 
For all cancers combined. 
RR, relative risk. 
Based only on patients with glomerulonephritis. 
population (20). 4) They include clearly defined 
patient populations rather than those subject to un- 
described referral patterns and other selection fac- 
tors. Additionally, two of the studies (21, 22) incor- 
porate the experience of dialysis patients who re- 
ceived a transplant, censoring their observation 
period at the time of transplantation. The inclusion 
of data on transplant recipients previously main- 
tained on dialysis, and hence the addition of further 
person-years of observation, results in a more com- 
prehensive estimate of cancer risk for dialysis pa- 
tients. 
In their research on 148 male patients treated at a 
Seattle area Veterans' Administration facility be- 
tween August 1966 and July 1977, Lindner and 
colleagues (23) observed that nine tumors of all sites 
were observed when less than four were expected 
based on a comparison with SEER data for the 
Seattle area. Since six of the nine observed tumors 
were lung cancers, the results were adjusted for 
smoking status, and a significant excess incidence of 
all sites of cancer combined persisted. 
The entire SEER data set was used to provide 
comparative cancer incidence data in a population- 
based study of 28,049 U.S. patients treated by di- 
alysis for at least 6 months from 1973 through 1977, 
and reported to the Health Care Financing Admin- 
istration (21). Tumors of the uterine cervix were 
excluded from analyses because their diagnosis may 
be a result of the frequency of medical observation. 
Since multiple myeloma and kidney neoplasms may 
explain chronic renal failure rather than arise sub- 
sequently, these tumors were excluded as well. Anal- 
yses were conducted by underlying renal disease, by 
interval from entry into the study, by type of dialysis, 
and by highest serum creatinine level prior to di- 
alysis. A significantly elevated risk of NHL was noted 
among patients with glomerulonephritis; data on 
cytotoxic therapy, however, were not available. Mod- 
erate, but statistically insignificant, excesses of leu- 
kemia, Hodgkin's disease, thyroid, and biliary tract 
cancers also were observed. 
A record linkage study of data collected by two 
population-based registries, the Michigan Kidney 
Registry and the Metropolitan Detroit Cancer Sur- 
veillance System (a SEER participant), reviewed the 
cancer experience of 4 16 1 patients in three counties 
of southeastern Michigan who were treated by di- 
alysis for ESRD between 1973 and 1984 (22). After 
adjusting for sex, age, race, and calendar year, a 
statistically significant excess of all in situ tumors 
combined was reported. This finding is probably a 
result of the increased surveillance of the patient 
population. More compelling was the 4.3- and 5.0- 
fold excess of, respectively, endometrial and renal 
neoplasms (both p < 0.005). A 1.7-fold increase ( p  
< 0.05) in prostate cancer also was observed. 
Available data for dialysis patients can be sum- 
marized as suggesting an increased risk of kidney 
cancers (14, 22); endometrial uterine cancer (22); 
and, among patients with glomerulonephritis, NHL 
(21). The overall cancer risk for all sites combined 
may be slightly increased. It should be noted here 
that this risk does not include the risk for skin 
cancers, since many studies have not evaluated these 
tumors. It is clear that more research is needed to 
further address the risks for specific sites of cancer 
as well as the particular risk factors. 
Potential Risk Factors for Cancer in Patients 
on Dialysis 
A myriad of factors related to ESRD and its treat- 
ment are potential contributors to an increased risk 
of malignancy. Alterations in host defense as a con- 
sequence of uremia, or uremic toxins, may accelerate 
or amplify the development of neoplasms (24, 25). 
An accumulation of polyamines, for example, has 
been shown to occur in patients on chronic dialysis 
(26). Chemical exposures via the dialysate also have 
been proposed as potentially increasing the risk of 
cancer (27, 28). Ethylene oxide, used widely for gas 
sterilization of dialyzers (29), is classified by the 
International Agency for Research on Cancer as a 
chemical with inadequate evidence of carcinogenic- 
ity in humans, but one with sufficient evidence of 
carcinogenicity from animal studies (30). Addi- 
tionally, the blood of dialysis patients is exposed to 
plasticizers, such as phthalate, and to spallation par- 
ticles which exert toxic effects on the hematopoietic 
and macrophage/reticuloendothelial system of ani- 
mals (3 1). 
Thus, hemodialysis patients whose blood is in 
contact with dialyzers, tubings, and approximately 
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100 liters of dialysate three times weekly have signif- 
icant exposure to potential carcinogens while renal 
excretion and the immune system are impaired. For 
peritoneal dialysis patients, essentially the same fac- 
tors apply except for the lack of the dialyzer and 
smaller dialysate volumes. The comparative risk for 
patients on hemodialysis versus peritoneal dialysis 
has not been studied adequately. 
Recommendations for Cancer Surveillance 
Before the issue of monitoring dialysis patients for 
cancer can be considered on a wide-scale basis, the 
question of whether these patients, or certain 
subgroups, are more likely than the general popula- 
tion to develop cancer must be resolved with greater 
certainty. The need to address this question in a 
scientifically sound fashion is well recognized ( 18, 
32,33). A study large enough to adjust for the length 
of time on dialysis, the type of dialysis, the age at 
onset of ESRD and dialysis therapy, and the primary 
renal disease should be undertaken. In addition, the 
inclusion of cancer risk factors beyond those associ- 
ated with dialysis should be considered in future 
studies designed to characterize the risk of cancer in 
patients treated by dialysis. 
At the present time, pending more definitive pop- 
ulation-based cohort studies, it would be premature 
to implement more rigorous cancer monitoring of 
all dialysis patients. Several studies have addressed 
this realm of patient care and have done so in a 
limited sense ( 14, 15, 34). However, from the avail- 
able data, one can consider some recommendations 
for routine monitoring of specific subgroups of di- 
alysis patients. Patients with certain forms of glo- 
merulonephritis are more often treated with immu- 
nosuppressive agents prior to ESRD, which may 
place this patient group at high risk of lymphoprolif- 
erative disease such as NHL (19). Occupational ex- 
posures to solvents and silica have been associated 
with ESRD (35), and such exposures also may influ- 
ence malignant transformation (36). Patients with a 
history of such exposures should continue to be 
closely followed. 
Certain conditions may be associated with the 
observed increased risk of renal neoplasms in dialysis 
patients (Table 3). A history of chronic analgesic use 
is associated with both ESRD and an increased risk 
of renal and other urinary tract cancers (37, 38). 
Dialysis patients with acquired cystic disease of the 
kidneys have been reported to be more likely to 
develop renal neoplasms (39-44). Since Dunnill’s 
original observation in 1977 (39) that a large fraction 
of maintenance dialysis patients can develop renal 
cysts over time, many reports have acknowledged 
that associated with this is a significant risk for renal 
cancers (42-44). Therefore, for patients with ac- 
quired renal cysts, one could consider annual renal 
ultrasound or computerized tomography in addition 
to a routine health maintenance examination (45, 
46). This applies mostly to patients on long-term 
dialysis, particularly those on dialysis 5 years or 
TABLE 3. Conditions associated with an increased cancer risk 
among dialysis patients 
Condition (Ref.) Cancer Site 
Glomerulonephritis ( 19) Non-Hodgkin’s lymphoma 
Analgesic nephropathy (37, 38) Kidney, urinary tract 
Acquired renal cysts (39-44) Kidney 
Prior transplant failure (47) Non-Hodgkin’s lymphoma 
Kaposi’s sarcoma 
Cervix (in situ tumors) 
Vulva 
Perineum 
more, as the risk of cystic transformation increases 
with time on dialysis. Careful evaluation of the kid- 
neys is essential, as a distinct solid lesion may be 
difficult to detect due to the distortion of the renal 
parenchyma ( 14). 
Dialysis patients with a prior renal transplant are 
another subgroup of patients who may face an in- 
creased risk of cancer. These patients must be con- 
sidered to have a carry-over risk from the transplant 
immunosuppression. The types of cancers which are 
most frequently diagnosed in this population include 
NHL (particularly reticulum cell sarcoma), Kaposi’s 
sarcoma, in situ cervical tumors, and carcinomas of 
the vulva and perineum (47). 
Conclusion 
In comparison to the general population, patients 
on dialysis may experience a slightly increased risk 
of all types of cancers combined. Unlike transplant 
recipients, the types of cancers most commonly di- 
agnosed in patients on dialysis are those most likely 
to be found in the general non-ESRD population. 
Further research is necessary to assess whether these 
excesses are found in dialysis patients belonging to 
discreet subgroups, such as those receiving a partic- 
ular mode of dialysis or having a particular primary 
renal disease. This is underscored by the results from 
the study of the nationwide cohort of dialysis patients 
in the United States, which found a significant excess 
risk only for NHL among patients with glomerulo- 
nephritis. In terms of specific sites of cancer, the 
evidence suggests that risk may be highest for renal 
and genitourinary neoplasms. Additional work is 
needed to allow a more refined estimate to be made 
of the magnitude of risk that exists for specific types 
of cancers. 
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